Back to News
M&A

Drinks With The Deal: Krishna Veeraraghavan of Paul Weiss

|
Published: October 14th, 2021
M&A lawyer Krishna Veeraraghavan talked about healthcare dealmaking and the risks of excessive antitrust regulation of combinations between biotech and pharma companies in the Drinks With The Deal podcast.

Sanofi SA’s (SNY) $3.2 billion acquisition of Translate Bio Inc. was a classic healthcare deal, said Krishna Veeraraghavan, a partner at Paul, Weiss, Rifkind, Wharton & Garrison LLP who advised the target on the deal.

Translate has cutting edge mRNA vaccine technology, while Sanofi “has a huge vaccine machine, in particular for the flu,” Veeraraghavan said. “This is a transaction where you have Translate Bio giving its technology, which is excellent, to a bigger company which has the ability to take it to the next level.”

Years ago, he said, “Big pharma made a decision that they were not effective at doing R&D. That has been outsourced to biotech companies,” an arrangement that has worked well for investors, companies and consumers. Increased skepticism of M&A in Washington and a greater willingness on the part of regulators to challenge deals risks discouraging innovation in the pharma and biotech sector, said Veereraghavan, who does a lot of work in the space.

“These deals are critical to bringing the smaller company’s product to the public,” he said. “Moderna was able to do it themselves, but they are the exception. To bar these transactions discourages innovation on the biotech side.” Historically, he said, regulators have realized that M&A is essential for the commercialization of useful drugs. “The deals that have happened have been helpful for patients.”

Here’s the podcast:

More podcasts from The Deal are available on iTunesSpotify and on TheDeal.com.

More From M&A

M&A

Drinks With The Deal: Cadence's Stone on Marine Corps Lessons

By David Marcus
|
Published: February 29th, 2024
On this week’s episode of Drinks With The Deal, Ryan Stone, a corporate development professional at Cadence Design Systems, discusses how an early stint in the Marine Corps helped shape his career.
M&A

Mizuho Eyes Bigger Slice of U.S. Middle Market

By Quratulain Tejani
|
Published: February 7th, 2024
Deals for Greenhill and Capstone are indicative of Mizuho's desire to expand in the U.S., particularly in the middle market with private companies and investors, head of the investment and corporate banking unit Michal Katz says.